Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Censoring Survival Data01:09

Censoring Survival Data

73
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
73
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

166
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
166
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

115
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
115
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

114
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
114
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

201
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
201
Actuarial Approach01:20

Actuarial Approach

69
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
69

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypoglycemia Occurrence and Risk Factors in Insulin Independent Patients After Total Pancreatectomy With Islet Autotransplantation.

Clinical transplantation·2026
Same author

Association Between Sensorineural Hearing Loss and Neurocognitive Performance in Survivors of Childhood Cancer: A Systematic Review and Meta-Analysis.

Cancer medicine·2025
Same author

Association of Left Atrial Function With Mitral Regurgitation: The Atherosclerosis Risk in Communities Study.

Journal of the American Heart Association·2025
Same author

Associations of Midlife Leukocyte Telomere Length With Measures of Left Atrial Function in Community-Dwelling Older Adults: The ARIC Study.

Journal of the American Heart Association·2025
Same author

Dose selection criteria to identify the optimal dose based on ranked efficacy-toxicity outcomes without reliance on clinical utilities.

Statistical methods in medical research·2025
Same author

Markers of Left Atrial Myopathy: Prognostic Usefulness for Ischemic Stroke and Dementia in People in Sinus Rhythm.

Stroke·2025
Same journal

A statistical evaluation of decision-making methods and the efficiency of Bayesian multi-arm multi-stage trials.

Clinical trials (London, England)·2026
Same journal

Accounting for non-adherence: A re-analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial.

Clinical trials (London, England)·2026
Same journal

Phase I design for partially ordered groups with late-onset toxicity.

Clinical trials (London, England)·2026
Same journal

Trial informed consent forms, the Declaration of Helsinki and the SPIRIT 2025 statement.

Clinical trials (London, England)·2026
Same journal

17th Annual University of Pennsylvania Conference on statistical issues in clinical trials - Covariate adjustment in randomized clinical trials: New methods and applications (Morning panel discussion).

Clinical trials (London, England)·2026
Same journal

17th Annual University of Pennsylvania Conference on statistical issues in clinical trials - Covariate adjustment in randomized clinical trials: New methods and applications (Afternoon panel discussion).

Clinical trials (London, England)·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K

Statistical approaches for component-wise censored composite endpoints.

Anne Eaton1

  • 1Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.

Clinical Trials (London, England)
|August 8, 2024
PubMed
Summary
This summary is machine-generated.

This study introduces new statistical methods to accurately analyze clinical trial data with composite endpoints, specifically addressing component-wise censoring for improved event-free survival estimation.

Keywords:
Composite endpointscensoringprogression-free survivaltime-to-event

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.4K

Related Experiment Videos

Last Updated: Jun 17, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.4K

Area of Science:

  • Biostatistics
  • Clinical Trials Methodology
  • Survival Analysis

Background:

  • Composite endpoints are frequently used in clinical trials, combining multiple events.
  • Component-wise censoring, where different events are censored differently, presents analytical challenges.
  • Existing methods may introduce bias when analyzing composite endpoints with mixed censoring types.

Purpose of the Study:

  • To develop and present statistical approaches for handling component-wise censoring in composite endpoints.
  • To accurately estimate event-free survival curves in the presence of mixed censoring.
  • To assess treatment effects on event-free survival using hazard ratios.

Main Methods:

  • Focus on composite endpoints including death (right censored) and a non-fatal event (interval censored).
  • Development of statistical methods specifically designed for component-wise censoring.
  • Application of these methods to analyze data from a randomized trial on infant feeding practices.

Main Results:

  • Proposed methods provide unbiased estimation of event-free survival.
  • Accurate hazard ratio estimation for treatment effects under component-wise censoring.
  • Demonstration of method's utility in a real-world clinical study.

Conclusions:

  • The developed statistical methods effectively address component-wise censoring in composite endpoints.
  • These approaches offer more reliable survival analysis for complex clinical trial data.
  • Accurate analysis is crucial for understanding treatment efficacy in studies with mixed censoring patterns.